Lead Product(s) : Lactulose
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cadila Pharma Launches Cadilose for Constipation, Hepatic Encephalopathy
Details : Cadilose is an advanced Lactulose formulation designed to effectively manage constipation and hepatic encephalopathy (HE).
Product Name : Cadilose
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : Lactulose
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifaximin,Lactulose
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bausch Health Announces Favorable Topline Results From Investigative Formulation of Rifaximin SSD IR
Details : In the study, the treatment arm evaluating 40 mg BID of rifaximin SSD IR plus standard of care therapy met its primary endpoint of time to resolution of OHE.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2020
Lead Product(s) : Rifaximin,Lactulose
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
